1. Home
  2. IVA vs BSVN Comparison

IVA vs BSVN Comparison

Compare IVA & BSVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IVA
  • BSVN
  • Stock Information
  • Founded
  • IVA 2011
  • BSVN 2004
  • Country
  • IVA France
  • BSVN United States
  • Employees
  • IVA N/A
  • BSVN N/A
  • Industry
  • IVA Biotechnology: Pharmaceutical Preparations
  • BSVN Major Banks
  • Sector
  • IVA Health Care
  • BSVN Finance
  • Exchange
  • IVA Nasdaq
  • BSVN Nasdaq
  • Market Cap
  • IVA 359.6M
  • BSVN 410.8M
  • IPO Year
  • IVA 2020
  • BSVN 2018
  • Fundamental
  • Price
  • IVA $5.32
  • BSVN $48.44
  • Analyst Decision
  • IVA Strong Buy
  • BSVN Buy
  • Analyst Count
  • IVA 6
  • BSVN 2
  • Target Price
  • IVA $15.33
  • BSVN $53.50
  • AVG Volume (30 Days)
  • IVA 71.1K
  • BSVN 20.3K
  • Earning Date
  • IVA 09-26-2025
  • BSVN 10-10-2025
  • Dividend Yield
  • IVA N/A
  • BSVN 1.98%
  • EPS Growth
  • IVA N/A
  • BSVN 36.51
  • EPS
  • IVA N/A
  • BSVN 4.65
  • Revenue
  • IVA $14,591,573.00
  • BSVN $96,069,000.00
  • Revenue This Year
  • IVA $80.35
  • BSVN N/A
  • Revenue Next Year
  • IVA N/A
  • BSVN $4.37
  • P/E Ratio
  • IVA N/A
  • BSVN $10.42
  • Revenue Growth
  • IVA N/A
  • BSVN 22.27
  • 52 Week Low
  • IVA $1.53
  • BSVN $32.49
  • 52 Week High
  • IVA $6.50
  • BSVN $50.26
  • Technical
  • Relative Strength Index (RSI)
  • IVA 58.63
  • BSVN 57.37
  • Support Level
  • IVA $5.27
  • BSVN $47.56
  • Resistance Level
  • IVA $5.75
  • BSVN $49.98
  • Average True Range (ATR)
  • IVA 0.39
  • BSVN 1.16
  • MACD
  • IVA 0.03
  • BSVN 0.08
  • Stochastic Oscillator
  • IVA 50.66
  • BSVN 71.96

About IVA Inventiva S.A. American Depository Shares

Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.

About BSVN Bank7 Corp. Common stock

Bank7 Corp is a full-service commercial bank focused on providing customers with exceptional service and meeting their banking needs through a variety of commercial and retail financial services. It offers deposit banking products, including commercial deposit services, commercial checking, money market, and other deposit accounts, and retail deposit services such as certificates of deposit, money market accounts, checking accounts, negotiable order of withdrawal accounts, savings accounts, and automated teller machine access. etc. It generates revenues from interest income from financial instruments and non-interest income and service charges on deposit accounts.

Share on Social Networks: